Targeting the PI3K/AKT/mTOR Pathway in Non-Hodgkin’s Lymphoma: Results, Biology, and Development Strategies
出版年份 2011 全文链接
标题
Targeting the PI3K/AKT/mTOR Pathway in Non-Hodgkin’s Lymphoma: Results, Biology, and Development Strategies
作者
关键词
-
出版物
Current Oncology Reports
Volume 13, Issue 5, Pages 398-406
出版商
Springer Nature
发表日期
2011-07-13
DOI
10.1007/s11912-011-0187-7
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Therapeutic Inhibition of MAP Kinase Interacting Kinase Blocks Eukaryotic Initiation Factor 4E Phosphorylation and Suppresses Outgrowth of Experimental Lung Metastases
- (2011) B. W. Konicek et al. CANCER RESEARCH
- Current and future directions in mammalian target of rapamycin inhibitors development
- (2011) Angelica Fasolo et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- CAL-101, a p110 selective phosphatidylinositol-3-kinase inhibitor for the treatment of B-cell malignancies, inhibits PI3K signaling and cellular viability
- (2010) B. J. Lannutti et al. BLOOD
- Novel agents for B-cell non-Hodgkin lymphoma: Science and the promise
- (2010) Kevin Tay et al. BLOOD REVIEWS
- Genetic Dissection of the Oncogenic mTOR Pathway Reveals Druggable Addiction to Translational Control via 4EBP-eIF4E
- (2010) Andrew C. Hsieh et al. CANCER CELL
- Pim kinase inhibitors: a survey of the patent literature
- (2010) Tina Morwick EXPERT OPINION ON THERAPEUTIC PATENTS
- Phase I study of the oral mammalian target of rapamycin inhibitor everolimus (RAD001) in Japanese patients with relapsed or refractory non-Hodgkin lymphoma
- (2010) Kensei Tobinai et al. INTERNATIONAL JOURNAL OF HEMATOLOGY
- Phase II Trial of the Oral Mammalian Target of Rapamycin Inhibitor Everolimus in Relapsed or Refractory Waldenström Macroglobulinemia
- (2010) Irene M. Ghobrial et al. JOURNAL OF CLINICAL ONCOLOGY
- A phase II trial of the oral mTOR inhibitor everolimus in relapsed aggressive lymphoma
- (2010) T E Witzig et al. LEUKEMIA
- mTORC1-Mediated Cell Proliferation, But Not Cell Growth, Controlled by the 4E-BPs
- (2010) R. J. O. Dowling et al. SCIENCE
- A proliferation-inducing ligand mediates follicular lymphoma B-cell proliferation and cyclin D1 expression through phosphatidylinositol 3-kinase-regulated mammalian target of rapamycin activation
- (2009) M. Gupta et al. BLOOD
- Inhibition of histone deacetylase overcomes rapamycin-mediated resistance in diffuse large B-cell lymphoma by inhibiting Akt signaling through mTORC2
- (2009) M. Gupta et al. BLOOD
- Translation initiation: a critical signalling node in cancer
- (2009) Francis Robert et al. EXPERT OPINION ON THERAPEUTIC TARGETS
- Enhancing mTOR-targeted cancer therapy
- (2009) Xuerong Wang et al. EXPERT OPINION ON THERAPEUTIC TARGETS
- An ATP-competitive Mammalian Target of Rapamycin Inhibitor Reveals Rapamycin-resistant Functions of mTORC1
- (2009) Carson C. Thoreen et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Phase III Study to Evaluate Temsirolimus Compared With Investigator's Choice Therapy for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma
- (2009) Georg Hess et al. JOURNAL OF CLINICAL ONCOLOGY
- Antitumor Activity and Mechanism of Action of the Cyclopenta[b]benzofuran, Silvestrol
- (2009) Regina Cencic et al. PLoS One
- Active-Site Inhibitors of mTOR Target Rapamycin-Resistant Outputs of mTORC1 and mTORC2
- (2009) Morris E Feldman et al. PLOS BIOLOGY
- Low-dose, single-agent temsirolimus for relapsed mantle cell lymphoma
- (2008) Stephen M. Ansell et al. CANCER
- Mammalian target of rapamycin (mTOR) pathway signalling in lymphomas
- (2008) Elias Drakos et al. EXPERT REVIEWS IN MOLECULAR MEDICINE
- Tumorigenic activity and therapeutic inhibition of Rheb GTPase
- (2008) K. J. Mavrakis et al. GENES & DEVELOPMENT
- Rapamycin shows anticancer activity in primary chronic lymphocytic leukemia cellsin vitro, as single agent and in drug combination
- (2008) Anna Åleskog et al. LEUKEMIA & LYMPHOMA
- Ki67 and PIM1 expression predict outcome in mantle cell lymphoma treated with high dose therapy, stem cell transplantation and rituximab: a Cancer and Leukemia Group B 59909 correlative science study
- (2008) Eric D. Hsi et al. LEUKEMIA & LYMPHOMA
- Rapamycin differentially inhibits S6Ks and 4E-BP1 to mediate cell-type-specific repression of mRNA translation
- (2008) A. Y. Choo et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started